CPMP Meeting Views Tallow Derivatives
The Committee for Proprietary Medicinal Products' 33rd plenary meeting,held at the European Medicines Evaluation Agency in mid-December, adopted a Position Paper for Production of Tallow Derivatives for Use in Pharmaceuticals (CPMP/1163/97).
The paper's publication followed the first joint workshop between the CPMP's Biotechnology Working Party, the European Plasma Fractionation Association and the European Association of the Plasma Products Industry on plasma-derived medicinal products, which was hosted by the EMEA earlier in December.
Topics included issues related to: plasma source material; inactivation/ removal of viruses, with a focus on removal of viruses by filtration; and consideration of potential effects of viral inactivation or removal processes on biological activity of plasma-derived medicinal products.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze